Acurx Pharmaceuticals, Inc. (ACXP)
$1.45-$0.02 (-1.37%) Today
Thomas L. Harrison - Director
Robert J. Deluccia - Director
Robert G. Shawah - OfficerAcurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
No Form 4 activity for ACXP in the last 90 days.
8 Form 4 filings on record, the earliest from Apr 22, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Carl Sailer - Director | Grant or award | Stock Option | 2,150 | $0.00 | - | |
| Jack H. Dean - Director | Grant or award | Stock Option | 2,150 | $0.00 | - | |
| James J. Donohue - Director | Grant or award | Stock Option | 2,150 | $0.00 | - | |
| Thomas L. Harrison - Director | Grant or award | Stock Option | 2,150 | $0.00 | - | |
| Joseph C. Scodari - Director | Grant or award | Stock Option | 2,150 | $0.00 | - | |
| Robert J. Deluccia - Director | Grant or award | Stock Option | 37,100 | $0.00 | - | |
| David P. Luci - Officer | Grant or award | Stock Option | 37,100 | $0.00 | - | |
| Robert G. Shawah - Officer | Grant or award | Stock Option | 25,900 | $0.00 | - |
Acurx Pharmaceuticals, Inc. (ACXP) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-04-22. The full record for ACXP runs to 8 Form 4 filings, the earliest from 2026-04-22. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ACXP were filed in the last 90 days.
No insider sales of ACXP were filed in the last 90 days.
This page tracks ACXP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ACXP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
